Resolutions from the Annual General Meeting of ViroGates A/S

BIRKERØD, DENMARK - ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation in health clinics and hospitals, today held its annual general meeting at the company headquarters, Banevænget 13, 3460 Birkerød, Denmark.

Reference is made to the company announcement no. 04-2025 of 7 April 2025, setting the agenda and proposals.

The following resolutions were passed:

1. Attorney-at-law Jens Folker-Bruun was elected chairman of the general meeting.
2. The general meeting approved the board’s report on the company’s business for 2024.
3. The annual report was approved.
4. It was resolved to transfer the loss of DKK 14,344,980 for the financial year 2024 to the following year.
5. An indicative vote approved the remuneration report.
6. Patrik Dahlen, Lars Kongsbak and Valérie Soulier were re-elected as board members.
7. It was resolved that the annual remuneration fee for the board’s work in 2025 will remain unchanged at DKK 150,000 for the chairman and DKK 75,000 for each of the other directors.
8. BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor for the company.
9. The proposal for amending Articles 2.3, 2.4, and 4.14 was unanimously approved by the participating shareholders, and proxies received by the board. However, the necessary quorum to approve the amendments according to the articles was not met, and the final approval is conditional upon a confirmatory vote at a new general meeting.
10. The proposal to authorize the Chairman of the meeting (with substitution rights) to register the decisions was approved.
11. Nothing related to this point on the agenda was resolved.

The announcement can be found at https://www.virogates.com/investor/announcements

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]

Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: [email protected]

About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation in health clinics and improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.